Tivic Health Systems, Inc. (TIVC) is a publicly traded company in the Healthcare — Medical - Specialties industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services.
Analysis Summary
Tivic Health Systems, Inc. reported revenue of $382000 in the most recent fiscal year, growing at a 5-year CAGR of -15.0%.
Trailing-twelve-month margins: gross margin 5.2%, operating margin 105.9%, net margin 120.2%.
At the current price of $0.26, TIVC has negative trailing earnings (P/E not meaningful) and an ROE of -165.44%. Market capitalisation stands at $0M.
Balance sheet quality for TIVC: current ratio of 20.1, net cash position of $6.2M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.26 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.07 |
| EV / EBITDA | -0.50 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -165.44% |
| Return on Invested Capital | -55.13% |
| Return on Assets | -57.74% |
| Gross Margin | 516.03% |
| Operating Margin | 10587.18% |
| Net Margin | 12019.23% |
Financial Health
| Debt / Equity | 0.84 |
| Current Ratio | 1.11 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -2.66 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| TIVC | Tivic Health Systems, Inc. | 0.07 | -165.4% | ||
| ALC | Alcon Inc. | $32.3B | 51.73 | 1.52 | 2.9% |
| 0A0D.L | Alcon Inc. | $27.1B | |||
| STE | STERIS plc | $20.5B | |||
| 0JZ2.L | Masimo Corporation | $9.5B | 9.69 | -21.0% | |
| 0QLQ.L | Ypsomed Holding AG | $4.8B | 16.75 | 4.97 | 29.7% |
| 0A05.L | Medacta Group S.A. | $2.2B |
Price Performance
| 1 month | +0.00% |
| 3 months | +0.00% |
| Year-to-date | -30.34% |
| 1 year | -67.21% |
| 3 years | -97.37% |
52-Week Range
| 52-week High | $6.95 |
| 52-week Low | $0.72 |
| Avg Volume (90d) | 769K |
Related companies: BBLG · BJDX · CNTX · HSCS · MRAI · NUWE · PETV
Explore sector: Healthcare · Medical - Specialties
More sections of TIVC: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks